The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has led to an unprecedented effort toward the development of an effective …

Colorectal cancer (CRC) is one of the most common cancers worldwide. Current therapies
such as surgery, chemotherapy, and radiotherapy encounter obstacles in preventing …

We have developed a COVID-19 vaccine, hAd5 S-Fusion+ N-ETSD, that expresses SARS-
CoV-2 spike (S) and nucleocapsid (N) proteins with modifications to increase immune …

There are increasing incidences and mortality rates for colorectal cancer in the world. It is
common for chemotherapy and radiation given to patients with colorectal cancer to cause …

Background Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate
antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1 …

Background FOLFOX plus bevacizumab is a standard of care (SOC) for first-line treatment of
microsatellite-stable metastatic colorectal cancer (MSS mCRC). This study randomized …

Abstract Lessons Learned Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely
administered to patients with advanced cancer. All patients developed CD4+ and/or CD8+ T …

Abstract First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although
promising platforms for use as cancer vaccines, are impeded in activity by naturally …

Gene therapy with viral vectors has significantly advanced in the past few decades, with
adenovirus being one of the most commonly employed vectors for cancer gene therapy …

Cancer is among the major leading causes of mortality globally, and chemotherapy is
currently one of the most effective cancer therapies. Unfortunately, chemotherapy is …